Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease

Cellular Physiology and Biochemistry

Volumn 29, Issue 5-6, 2012, Pages 775-790

  Leier, Geraldine ^a   Bangel Ruland, Nadine ^a   Sobczak, Katja ^a   Knieper, Yvonne ^a   Weber, Wolf Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

CFTR; CGMP; Corrector; Cystic fibrosis; Potentiator; Xenopus laevis oocyte

Indexed keywords

CYCLIC AMP; CYCLIC GMP; SILDENAFIL; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CAPACITANCE; CONDUCTANCE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG MECHANISM; EPITHELIUM CELL; EXOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOPUS LAEVIS;

XENOPUS LAEVIS;

EID: 84861354967     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000265129     Document Type: Article

References (52)

1. Dormer RL, Harris CM, Clark Z, Pereira MM, Doull IJ, Norez C, Becq F, McPherson MA: Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005;60:55-59. (Pubitemid 40101019)
2. Lubamba B, Lecourt H, Lebacq J, Lebecque P, de Jonge HR, Wallemacq P, Leal T: Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008;177:506-515. (Pubitemid 351442189)
3. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073. (Pubitemid 19231814)
4. Anderson MP, Gregory RJ, Thompson S, Souza DW, Paul S, Mulligan RC, Smith AE, Welsh MJ: Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 1991;253:202-205. (Pubitemid 21917143)
5. Pilewski JM, Frizzell RA: Role of CFTR in airway disease. Physiol Rev 1999;79:S215-S255. (Pubitemid 29058916)
6. Ostedgaard LS, Baldursson O, Welsh MJ: Regulation of the cystic fibrosis transmembrane conductance regulator Clchannel by its R domain. J Biol Chem 2001;276:7689-7692.
7. Berger HA, Travis SM, Welsh MJ: Regulation of the cystic fibrosis transmembrane conductance regulator Clchannel by specific protein kinases and protein phosphatases. J Biol Chem 1993;268:2037-2047. (Pubitemid 23033611)
8. French PJ, Bijman J, Edixhoven M, Vaandrager AB, Scholte BJ, Lohmann SM, Nairn AC, de Jonge HR: Isotype-specific activation of cystic fibrosis transmembrane conductance regulatorchloride channels by cGMP-dependent protein kinase II. J Biol Chem 1995;270:26626-26631.
9. Vaandrager AB, Tilly BC, Smolenski A, Schneider-Rasp S, Bot AG, Edixhoven M, Scholte BJ, Jarchau T, Walter U, Lohmann SM, Poller WC, de Jonge HR: cGMP stimulation of cystic fibrosis transmembrane conductance regulator Clchannels co-expressed with cGMPdependent protein kinase type II but not type Ibeta. J Biol Chem 1997;272:4195-4200. (Pubitemid 27078487)
10. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990;63:827-834. (Pubitemid 120035055)
11. Ward CL, Kopito RR: Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins. J Biol Chem 1994;269:25710-25718.
12. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992;358:761-764.
13. Farmen SL, Karp PH, Ng P, Palmer DJ, Koehler DR, Hu J, Beaudet AL, Zabner J, Welsh MJ: Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005;289:L1123-L1130. (Pubitemid 41681347)
14. Johnson LG, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21-25.
15. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB: CFTR is a conductance regulator as well as a chloride channel. Physiol Rev 1999;79:S145-S166. (Pubitemid 29058912)
16. Kunzelmann K, Schreiber R: CFTR, a regulator of channels. J Membr Biol 1999;168:1-8. (Pubitemid 29128256)
17. Riordan JR: CFTR function and prospects for therapy. Annu Rev Biochem 2008;77:701-726.
18. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, Collawn JF: Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 2010;42:363-372.
19. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P: Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130. (Pubitemid 43830856)
20. Illek B, Fischer H: Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 1998;275:L902-L910.
21. Antoniu SA: Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Expert Opin Investig Drugs 2011;20:423-425.
22. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS: Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-2571. (Pubitemid 41266219)
23. Varga K, Goldstein RF, Jurkuvenaite A, Chen L, Matalon S, Sorscher EJ, Bebok Z, Collawn JF: Enhanced cell-surface stability of rescued DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem J 2008;410:555-564. (Pubitemid 351429026)
24. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, Thomas DY: Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 2011;18:231-242.
25. Wang Y, Loo TW, Bartlett MC, Clarke DM: Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR) - processing mutants by binding to the protein. J Biol Chem 2007;282:33247-33251. (Pubitemid 350159496)
26. Loo TW, Bartlett MC, Clarke DM: Correctors promote folding of the CFTR in the endoplasmic reticulum. Biochem J 2008;413:29-36. (Pubitemid 351946859)
27. O'Grady SM, Jiang X, Maniak PJ, Birmachu W, Scribner LR, Bulbulian B, Gullikson GW: Cyclic AMP-dependent Cl-secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J Membr Biol 2002;185:137-144. (Pubitemid 34095244)
28. Corbin JD, Francis SH: Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274:13729-13732.
29. Poschet JF, Timmins GS, Taylor-Cousar JL, Ornatowski W, Fazio J, Perkett E, Wilson KR, Yu HD, de Jonge HR, Deretic V: Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007;293:L712-L719. (Pubitemid 47358834)
30. Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, Hanrahan JW, Thomas DY: Correctors of protein trafficking defects identified by a novel high-throughput screening assay. Chembiochem 2007;8:1012-1020. (Pubitemid 47189285)
31. Lubamba B, Lebacq J, Reychler G, Marbaix E, Wallemacq P, Lebecque P, Leal T: Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice. Eur Respir J 2011;37:72-78.
32. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA: Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-1404. (Pubitemid 28221980)
33. Goldenberg MM: Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998;20:1033-1048. (Pubitemid 29058409)
34. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164-2171. (Pubitemid 29190800)
35. Koesling D, Mullershausen F, Lange A, Friebe A, Mergia E, Wagner C, Russwurm M: Negative feedback in NO/cGMP signalling. Biochem Soc Trans 2005;33:1119-1122. (Pubitemid 41659128)
36. Jiang LH, Gawler DJ, Hodson N, Milligan CJ, Pearson HA, Porter V, Wray D: Regulation of cloned cardiac L-type calcium channels by cGMP-dependent protein kinase. J Biol Chem 2000;275:6135-6143. (Pubitemid 30129898)
37. + channels encoded by the human ether-a-gogo-related gene-1 (hERG1) by nitric oxide. Mol Pharmacol 1999;56:1298-1308.
38. Weber WM, Cuppens H, Cassiman JJ, Clauss W, Van Driessche W: Capacitance measurements reveal different pathways for the activation of CFTR. Pflugers Arch 1999;438:561-569. (Pubitemid 29419913)
39. Kusche-Vihrog K, Sobczak K, Bangel N, Wilhelmi M, Nechyporuk-Zloy V, Schwab A, Schillers H, Oberleithner H: Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflugers Arch 2008;455:849-857. (Pubitemid 350265623)
40. + . Cell Physiol Biochem 2009;23:9-24.
41. Kelly SM, Butler JP, Macklem PT: Control of cell volume in oocytes and eggs from Xenopus laevis. Comp Biochem Physiol A Physiol 1995;111:681-691.
42. Cobb BR, Fan L, Kovacs TE, Sorscher EJ, Clancy JP: Adenosine receptors and phosphodiesterase inhibitors stimulate Clsecretion in Calu-3 cells. Am J Respir Cell Mol Biol 2003;29:410-418. (Pubitemid 37094001)
43. Meng QH, Springall DR, Bishop AE, Morgan K, Evans TJ, Habib S, Gruenert DC, Gyi KM, Hodson ME, Yacoub MH, Polak JM: Lack of inducible nitric oxide synthase in bronchial epithelium: a possible mechanism of susceptibility to infection in cystic fibrosis. J Pathol 1998;184:323-331. (Pubitemid 28112790)
44. Gruenert DC, Willems M, Cassiman JJ, Frizzell RA: Established cell lines used in cystic fibrosis research. J Cyst Fibros 2004;3 Suppl 2:191-196. (Pubitemid 40045597)
45. Dragomir A, Bjorstad J, Hjelte L, Roomans GM: Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004;322:447-451. (Pubitemid 39490324)
46. Ehrhardt C, Collnot EM, Baldes C, Becker U, Laue M, Kim KJ, Lehr CM: Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-. Cell Tissue Res 2006;323:405-415. (Pubitemid 43228096)
47. Schmidt A, Hughes LK, Cai Z, Mendes F, Li H, Sheppard DN, Amaral MD: Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol 2008;153:1311-1323. (Pubitemid 351415497)
48. Gresser U, Gleiter CH: Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature. Eur J Med Res 2002;7:435-446.
49. McCullough AR: Four-year review of sildenafil citrate. Rev Urol 2002;4 Suppl 3:S26-S38.
50. Toward TJ, Smith N, Broadley KJ: Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004;169:227-234. (Pubitemid 38114539)
51. Rückes-Nilges C, Weber U, Lindemann H, Munker G, Clauss W, Weber WM: Minor role of Cl-secretion in non-cystic fibrosis and cystic fibrosis human nasal epithelium. Cell Physiol Biochem 1999;9:1-10. (Pubitemid 29264199)
52. Robert R, Carlile GW, Pavel C, Liu N, Anjos SM, Liao J, Luo Y, Zhang D, Thomas DY, Hanrahan JW: Structural analog of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol Pharmacol 2008;73:478-489. (Pubitemid 351159218)